JPMorgan upgrades Rapt Therapeutics stock rating to Neutral from Underweight

Published 30/07/2025, 08:18
JPMorgan upgrades Rapt Therapeutics stock rating to Neutral from Underweight

Investing.com - JPMorgan has upgraded Rapt Therapeutics (NASDAQ:RAPT) from Underweight to Neutral and established a price target of $14.00 with a December 2026 time horizon. The stock, currently trading at $11.53, has seen a significant 17% decline over the past week, though InvestingPro analysis indicates the company is currently undervalued.

The upgrade reflects JPMorgan’s assessment that the company’s lead drug candidate RPT904 has a de-risked mechanism with significant potential in Food Allergy (FA) and Chronic Spontaneous Urticaria (CSU) markets. According to InvestingPro data, RAPT maintains a strong financial position with more cash than debt and a healthy current ratio of 21.11, providing runway for its drug development programs.

JPMorgan noted that Food Allergy represents a massive market opportunity where even capturing incremental market share could result in a blockbuster opportunity for Rapt Therapeutics.

The firm also views Chronic Spontaneous Urticaria as a sizable market opportunity that could independently drive upside for Rapt shares.

Despite the positive outlook on these opportunities, JPMorgan indicated that RPT904 remains "somewhat under-the-radar" following previous pipeline setbacks, and may require company-sponsored data to increase visibility of the asset.

In other recent news, Rapt Therapeutics has been the focus of significant developments. H.C. Wainwright raised its price target for the company to $27 from $6, maintaining a Buy rating. This adjustment follows Merck (NSE:PROR)’s announcement of acquiring Verona Pharma (NASDAQ:VRNA) for $10 billion. Additionally, Rapt Therapeutics has expanded its Board of Directors, appointing Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D. Both will serve on key committees, with Dr. Braunstein joining the Audit Committee and Dr. Dombkowski joining the Nominating and Corporate Governance Committee. The company also announced a 1-for-8 reverse stock split, set to take effect on June 16, 2025. Clear Street analysts initiated coverage of Rapt Therapeutics with a Buy rating and a price target of $3. They expressed confidence in the potential of RPT904, an anti-IgE antibody for food allergy and chronic spontaneous urticaria. Despite a 76% stock decline over the past year, analysts see a substantial opportunity due to the company’s cash reserves.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.